Through a communication to the public opinion, the Directorate of Medicines and Biological Products of the National Institute of Medicines and Food Surveillance, Invima, reported that it has not found any reason to suspend the sale of the drug diclofenac.
Add the information of the control entity that “To date, Invima has not identified any lot of injectable, oral or topical Diclofenac with quality deviations or microbiological contamination, which prevents marketing and, therefore, the use according to the indications approved in the sanitary registry”.
With this institutional information, it seeks to clarify the news spread on social networks about the drug diclofenac.
Can read. Invima director leaves, did shortage of medicines take its toll?
Add the information that is to clarify about two news broadcast on Whatsapp and other social networks, about the administration of the drug Diclofenac in a patient and the alleged association with a fatal outcome, in a clinic in the city of Barranquilla.
The information from Invima clarifies that this news was known in 2017 and they want to put it as a fact that it would be happening in this 2023, which “is completely far from reality.”
Another case that is reviewed in the Invima information is related to a possible death of a person associated with the drug diclofenac.
Based on the facts, were activated in conjunction with the Territorial Directorate of Health of the District of Barranquillathe inquiry and investigation necessary to clarify the facts and determine the real causes of death.
As it is a fact under investigation, to date what happened has not been clarified.
in advance, andl Invima emphasizes that the conclusions are pending to apply the pharmacovigilance or inspection, surveillance and control actions that are required.
You can also read. Invima issues international alert for ophthalmic ointment
The entity also clarifies that once the necessary and essential information is available to evaluate the described case, if applicable, The necessary measures will be taken to protect public health.
Invima highlights that it has formal and adequate mechanisms for the notification of adverse events associated with drugsTherefore, this institute recommends using these communication channels and contacting health institutions for the report, and avoiding misinformation in informal channels that can divert the objectivity and veracity of the notification.
